• Explore /
  • Poster
  • / The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.

The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.

Abstract Poster

Authors

null

Li Chen

Cancer Center, Fudan University, Shanghai, China

Li Chen , Shao Zhimin , Zhonghua Wang , Wentao Yang , Yizhou Jiang , Songyang Wu , Jiong Wu , Genhong Di , Guangyu Liu , Keda Yu , Lei Fan , Junjie Li , Yifeng Hou , Zhen Hu , Canming Chen , Xiaoyan Huang , Ayong Cao , Xin Hu , Xiaoyu Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT04129996

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1086)

DOI

10.1200/JCO.2023.41.16_suppl.1086

Abstract #

1086

Poster Bd #

307

Abstract Disclosures

Similar Posters

First Author: Shao Zhimin

First Author: Yun Zhang

First Author: Yuan-Yuan Qu

First Author: Shui-Ling Jin